Cardiff University | Prifysgol Caerdydd ORCA
Online Research @ Cardiff 
WelshClear Cookie - decide language by browser settings

Itaconic acid mediates crosstalk between macrophage metabolism and and peritoneal tumors

Weiss, Jonathan, Davies, Luke C., Karwan, Megan, Ileva, Lilia, Andrews, Caroline, Cheng, Robert, Ridnour, Lisa, Wink, David and McVicar, Daniel 2018. Itaconic acid mediates crosstalk between macrophage metabolism and and peritoneal tumors. Journal of Clinical Investigation 128 (9) , pp. 3794-3805. 10.1172/JCI99169

[thumbnail of 99169.3-20180821164919-covered-253bed37ca4c1ab43d105aefdf7b5536.pdf]
Preview
PDF - Published Version
Available under License Creative Commons Attribution.

Download (2MB) | Preview

Abstract

Control of cellular metabolism is critical for efficient cell function, although little is known about the interplay between cell subset–specific metabolites in situ, especially in the tumor setting. Here, we determined how a macrophage-specific (Mϕ-specific) metabolite, itaconic acid, can regulate tumor progression in the peritoneum. We show that peritoneal tumors (B16 melanoma or ID8 ovarian carcinoma) elicited a fatty acid oxidation–mediated increase in oxidative phosphorylation (OXPHOS) and glycolysis in peritoneal tissue–resident macrophages (pResMϕ). Unbiased metabolomics identified itaconic acid, the product of immune-responsive gene 1–mediated (Irg1-mediated) catabolism of mitochondrial cis-aconitate, among the most highly upregulated metabolites in pResMϕ of tumor-bearing mice. Administration of lentivirally encoded Irg1 shRNA significantly reduced peritoneal tumors. This resulted in reductions in OXPHOS and OXPHOS-driven production of ROS in pResMϕ and ROS-mediated MAPK activation in tumor cells. Our findings demonstrate that tumors profoundly alter pResMϕ metabolism, leading to the production of itaconic acid, which potentiates tumor growth. Monocytes isolated from ovarian carcinoma patients’ ascites fluid expressed significantly elevated levels of IRG1. Therefore, IRG1 in pResMϕ represents a potential therapeutic target for peritoneal tumors.

Item Type: Article
Date Type: Publication
Status: Published
Schools: Medicine
Publisher: American Society for Clinical Investigation
ISSN: 0021-9738
Funders: Wellcome Trust
Date of First Compliant Deposit: 29 May 2018
Date of Acceptance: 12 June 2019
Last Modified: 14 May 2023 03:07
URI: https://orca.cardiff.ac.uk/id/eprint/111835

Citation Data

Cited 142 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item Edit Item

Downloads

Downloads per month over past year

View more statistics